By mimicking the effects of a natural hormone, Semaglutide increases insulin secretion and decreases glucagon levels, leading to reduced food intake and a sense of fullness
However, timelines can shift based on trial results and regulatory requirements
Ozempic and Wegovy, which both contain semaglutide, work by mimicking a hormone called GLP-1 that triggers an increase in the production of insulin, slows the rate at which food is digested in the stomach and reduces appetite
One could take this argument further and draw parallels with diseases unequivocally known to be caused by an exogenous agent, such as tuberculosis
However, achieving this requires careful consideration, and most healthcare providers are not yet familiar with how to optimize microdosing strategies
If inflammation is part of the treatment conversation, your physician should look at more than the scale